Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. [Ensayo fase II randomizado para la caracterización de la neurotoxicidad de nab-paclitaxel versus paclitaxel convencional en primera línea de cáncer de mama metastásico HER2-negativo.]

Trial Profile

Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. [Ensayo fase II randomizado para la caracterización de la neurotoxicidad de nab-paclitaxel versus paclitaxel convencional en primera línea de cáncer de mama metastásico HER2-negativo.]

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top